Skip to main content

Table 3 Relation between tumor response and metabolic toxicities

From: Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

 

CTC Grade of Toxicities

Highest change in biological parameters

Median time to CTC Grade ≥ 2 toxicities

CB (%) / PD (%) (p)

CB (%) / PD (%) (p)

CB (days) / PD (days)

Lymphopenia

  

NA / 84 (0.01)

Increase in serum creatinine

92 / 46 (0.01)

+61 / -5 (0.002)

 

Hyperglycemia

  

56/112 (0.03)

Hypophosphatemia

 

−26 / -9 (0.02)

 

Increase in ASAT

94 / 66 (0.04)

+126 / +8 (0.004)

 

Increase in ALAT

100 / 66 (0.01)

+229 / +4 (0.003)

 

Hypercholesterolemia

   

Hypertriglyceridemia

   
  1. CB Clinical Benefit, PD Progressive Disease, NA not attained